{"": [120, 131, 0, 132, 1888, 0], "Introduction": [1889, 7681, 0], "Protein expression and purification": [7705, 10541, 0], "ELISA binding assays": [10542, 11650, 0], "Biolayer interferometry": [11651, 12731, 0], "VSV-spike pseudovirus production and neutralization assay": [12732, 14774, 0], "Plaque reduction neutralization test (PRNT)": [14775, 15705, 0], "Negative stain electron microscopy": [15706, 16256, 0], "Animal experiments": [16257, 17842, 0], "Quantitative RT-PCR assay for SARS-CoV-2 RNA": [17843, 18555, 0], "Quantitative RT-PCR assay for SARS-CoV-2 subgenomic RNA": [18556, 19427, 0], "Histopathology": [19428, 19938, 0], "Severity grading scale": [19939, 22612, 0], "Statistical analysis": [22613, 23231, 0], "Materials and methods": [7682, 23231, 1], "Generation of trimeric spike protein with or without nanoparticle presentation": [23241, 25397, 0], "In-vitro characterization and comparison of spike NP and non-NP": [25398, 29110, 0], "Immunogenicity of spike NP and non-NP in mice": [29111, 32726, 0], "Protection efficacy of spike NP in hamsters": [32727, 37812, 0], "Results": [23232, 37812, 1], "Discussion": [37813, 44663, 0], "Supplementary Material": [44664, 44763, 0]}